Grifols Partnering 2005-2012
Publisher Name » Current Partnering
Published Date » 2012-06-01
No. Of Pages » 100
This report provides all the information you require to better understand Grifols and its partnering interests and activities over the past seven years.
One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.
The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.
Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.
The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.
The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.
One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.
Understanding the flexibility of prospective partners negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.
In addition, contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.
In summary, the report provides the user with the tools to make successful contact with the right partners effectively and efficiently.
One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.
The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.
Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.
The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.
The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.
One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.
Understanding the flexibility of prospective partners negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.
In addition, contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.
In summary, the report provides the user with the tools to make successful contact with the right partners effectively and efficiently.
Executive Summary
Chapter 1 Introduction
Chapter 2 Biopharma top 50 and dealmaking activity
2.1 Biopharma partnering activity
2.2 Biopharma M&A activity
Chapter 3 Top bigpharma deals by value
3.1 Bigpharma M&A
3.2 Bigpharma partnering
Chapter 4 Submitting Opportunities to Prospective Partners
4.1 How to submit an opportunity
4.2 Opportunity submission template
4.3 Sending emails
4.4 Face to face at partnering events
4.5 Online submission forms
Chapter 5 Forthcoming partnering events
Chapter 6 Company Profile
6.1 How to use company profiles
6.2 Field definitions
6.3 Company profile
Partnering deals directory (2005-present) - by industry sector
Bigpharma
Pharmaceutical
Biotech
Diagnostic
Drug delivery
Government
Medical device
Consumer health
Specialty pharma
Generic pharma
Agricultural
Animal health
Academic
Non-profit
Research tools
Services
Partnering deals directory (2005-present) - By deal type
Asset purchase
Co-Development
Co-Market
Co-Promotion
Collaborative R&D
Contract service
Development
Distribution
Evaluation
Joint venture
Licensing
Manufacture
Marketing
Promotion
Research
Royalty financing
Supply
Partnering deals directory (2005-present) M&A
Partnering deals directory (2005-present) - By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Partnering deals directory (2005-present) - By therapy area
Hospital care
Cardiovascular
Central nervous system
Cosmetic
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hemotology
Immunology
Infectives
Inflammatory
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Respiratory
Sensory organ
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form Reports
Order Form Partnering Agreements Company Profiles
TABLE OF FIGURES
Figure 1: Bigpharma partnering activity top 50 by pharma sales
Figure 2: Bigpharma M&A activity top 50 by pharma sales
Figure 3: Leading M&A deals involving bigpharma by value, 2005-2011
Figure 4: Leading partnering deals by value, 2005-2011
Figure 5: Typical partnering opportunity submission template
Figure 6: Company profile template and definitions used in report
Figure 7: Dealmaking frequency 2005-2011
Figure 8: Current partner companies (2005-present)
Figure 9: Partnering deals by type (2005-present)
Figure 10: Recent deals (2005-present) by industry sector
Figure 11: Recent deals (2005-present) by deal type
Figure 12: Recent deals (2005-present) by stage of development
Figure 13: Recent deals (2005-present) by therapy area
Chapter 1 Introduction
Chapter 2 Biopharma top 50 and dealmaking activity
2.1 Biopharma partnering activity
2.2 Biopharma M&A activity
Chapter 3 Top bigpharma deals by value
3.1 Bigpharma M&A
3.2 Bigpharma partnering
Chapter 4 Submitting Opportunities to Prospective Partners
4.1 How to submit an opportunity
4.2 Opportunity submission template
4.3 Sending emails
4.4 Face to face at partnering events
4.5 Online submission forms
Chapter 5 Forthcoming partnering events
Chapter 6 Company Profile
6.1 How to use company profiles
6.2 Field definitions
6.3 Company profile
Partnering deals directory (2005-present) - by industry sector
Bigpharma
Pharmaceutical
Biotech
Diagnostic
Drug delivery
Government
Medical device
Consumer health
Specialty pharma
Generic pharma
Agricultural
Animal health
Academic
Non-profit
Research tools
Services
Partnering deals directory (2005-present) - By deal type
Asset purchase
Co-Development
Co-Market
Co-Promotion
Collaborative R&D
Contract service
Development
Distribution
Evaluation
Joint venture
Licensing
Manufacture
Marketing
Promotion
Research
Royalty financing
Supply
Partnering deals directory (2005-present) M&A
Partnering deals directory (2005-present) - By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Partnering deals directory (2005-present) - By therapy area
Hospital care
Cardiovascular
Central nervous system
Cosmetic
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hemotology
Immunology
Infectives
Inflammatory
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Respiratory
Sensory organ
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form Reports
Order Form Partnering Agreements Company Profiles
TABLE OF FIGURES
Figure 1: Bigpharma partnering activity top 50 by pharma sales
Figure 2: Bigpharma M&A activity top 50 by pharma sales
Figure 3: Leading M&A deals involving bigpharma by value, 2005-2011
Figure 4: Leading partnering deals by value, 2005-2011
Figure 5: Typical partnering opportunity submission template
Figure 6: Company profile template and definitions used in report
Figure 7: Dealmaking frequency 2005-2011
Figure 8: Current partner companies (2005-present)
Figure 9: Partnering deals by type (2005-present)
Figure 10: Recent deals (2005-present) by industry sector
Figure 11: Recent deals (2005-present) by deal type
Figure 12: Recent deals (2005-present) by stage of development
Figure 13: Recent deals (2005-present) by therapy area
List of Tables
NAList of Figures
NAUpcoming Reports:
|
Oral Hygiene Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts, 2012 - 2018
By - Transparency Market Research
An increase in ageing population and rising demand for oral care are offering enormous opportunities for product innovations and developments to oral care providers. Rising awareness of oral care and the quality of services provided by dental care providers are some important factors driving the oral hygiene market. In addition to this, innovative products development and rising demand for aesthetic dentistry in developing nations is expected to drive the growth of the oral hygiene industry.
Emerging technologies will have a great impact on the overall growth of this...
|
|
Gas Sensors Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012-2018
By - Transparency Market Research
The gas sensors market for gas flow meters and gas flow sensors is experiencing considerable changes over the past few years. The major reasons for the continuous fluctuations in the gas sensors market are technological developments, and economic crisis. This market is now expected to witness versatile growth in the coming years due to advancement in gas sensor technology and implementation of these sensors in different applications.
Gas sensors are finding a number of applications in different industries. Electrochemical gas sensors are used to detect toxic gases, while IR...
|
|
Meal Replacement Products Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts, 2012 - 2018
By - Transparency Market Research
Rising obesity figures and lesser time available for preparing whole meals are some of the major reasons contributing to the growth of the meal replacement products market.
This industry remained unaffected during the economic recession as the products available are much cheaper than equivalent weight loss services and related methods. Despite increase in competition from weight loss services industry and recovery of world economy, revenue growth of the meal replacement market remains stable due to higher disposable incomes and rising health consciousness. ...
|
Research Assistance
We will be happy to help you find what you need.
Please call us or write us:
Please call us or write us:
866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Email: sales@researchmoz.com
Select License type:
Share this report
Latest Reports
- The Future of the Haircare Market in Egypt to 2017
- The Future of the Haircare Market in Denmark to 2017
- Overview of international chemical market
- Russian market of microcredits and lending to SME in Russia
- Overview of furniture market
- Global and China Piano Industry Report, 2012-2013
- The Future of the Haircare Market in Czech Republic to 2017
- LTE Strategy 2013 - 2018
- Natural And Synthetic (Ethoxyquin, BHA, BHT) Animal Feed Antioxidants Market For Swine, Poultry, Cattle And Aquaculture - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
- Seed Treatment Market (Insecticides, Fungicides, Other Chemical And Nonchemical Treatment) For Corn, Soybean, Wheat, Canola, Cotton And Others - Global Industry Analysis, Size, Share, Growth And Forecast, 2012 - 2018
Related News
|
One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
|
|
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples.
The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
|
|
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
|
|
Battling against flu, vaccination necessary for health workers
Sep 14, 2012
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease.
Health officials...
|
|
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...
|
